Mustafa Pehlivan was born in 1990 in Cyprus. He graduated from an English teaching high school college. In 2015, he graduated from the University Of Hertfordshire as a Bachelor in Pharmaceutical Health Science. Currently he is studying Pharmacy at Cyprus International University (Cyprus) and he will be soon completing his degree in Pharmacy also. He is currently holding an Internationally filed Pharmaceutical patent.
The purpose of this paper is to introduce a newly discovered anti androgen compound (pentabromo-dicyclohexane) which has a very high potential of being used as a medicine to treat prostate cancer and reduce the symptoms of cancer. The molecule has been discovered based on the Target predictor tool, Swiss, which is an online software used for drug discovery trials. It is evidenced in this paper why this compound will work better than any other drugs available to treat cancer based on statistical and enzymatic target binding activities.